Pliant Therapeutics Inc (NASDAQ: PLRX) kicked off on Monday, down -8.16% from the previous trading day, before settling in for the closing price of $1.47. Over the past 52 weeks, PLRX has traded in a range of $1.26-$16.52.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -52.88% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 23.99%. With a float of $52.99 million, this company’s outstanding shares have now reached $60.86 million.
In an organization with 171 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Pliant Therapeutics Inc (PLRX) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Pliant Therapeutics Inc is 13.46%, while institutional ownership is 100.17%. The most recent insider transaction that took place on Jan 17 ’25, was worth 587,150. In this transaction President and CEO of this company sold 52,419 shares at a rate of $11.20, taking the stock ownership to the 430,517 shares. Before that another transaction happened on Jan 17 ’25, when Company’s Chief Financial Officer sold 20,148 for $11.20, making the entire transaction worth $225,680. This insider now owns 262,608 shares in total.
Pliant Therapeutics Inc (PLRX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.62 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 23.99% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.00% during the next five years compared to -78.30% drop over the previous five years of trading.
Pliant Therapeutics Inc (NASDAQ: PLRX) Trading Performance Indicators
Take a look at Pliant Therapeutics Inc’s (PLRX) current performance indicators. Last quarter, stock had a quick ratio of 10.91.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.47, a number that is poised to hit -0.77 in the next quarter and is forecasted to reach -2.43 in one year’s time.
Technical Analysis of Pliant Therapeutics Inc (PLRX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.46 million. That was inferior than the volume of 2.64 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 15.81%. Additionally, its Average True Range was 0.29.
During the past 100 days, Pliant Therapeutics Inc’s (PLRX) raw stochastic average was set at 0.61%, which indicates a significant decrease from 4.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 68.78% in the past 14 days, which was lower than the 228.66% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.7816, while its 200-day Moving Average is $10.8610. However, in the short run, Pliant Therapeutics Inc’s stock first resistance to watch stands at $1.4100. Second resistance stands at $1.4700. The third major resistance level sits at $1.5100. If the price goes on to break the first support level at $1.3100, it is likely to go to the next support level at $1.2700. Assuming the price breaks the second support level, the third support level stands at $1.2100.
Pliant Therapeutics Inc (NASDAQ: PLRX) Key Stats
The company with the Market Capitalisation of 82.67 million has total of 61,236K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -210,300 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -49,730 K.
